Introduction
The US is the leading global drugs market in terms of sales and profit margin. However, drug companies are facing an unprecedented number of challenges in maintaining revenue growth: fewer drugs are being approved, a wide number of blockbusters are facing patent expiry, and payers are implementing stringent cost-containment policies in the face of sky-rocketing healthcare costs.

Scope
Identification of the pressures facing the drugs industry and examination of the implications for P&R
Overview of the US healthcare market, focusing on identifying key P&R stakeholders
In-depth analysis of global P&R controls, examining which are important in the US market both currently and in the future
Best-practice recommendations to help drugs companies capitalize on pricing and reimbursement opportunities to maximize drug ROI
Highlights
US drug developers need to prioritize P&R as an important factor in drug development, and in particular should place significant emphasis on performing robust pharmacoeconomic analysis to strengthen the case for setting a strong launch price and securing adequate reimbursement.

Drug developers should increasingly focus on securing strong P&R justification before green-lighting me-too drugs. If it is not possible to clearly differentiate the drug, then the developer should carefully assess potential ROI, and consider discontinuing development if necessary to optimize resource allocation.

To capitalize on changes to the P&R environment, drugs companies must optimize P&R team interaction both internally with other teams such as brand management, and externally with payer decision-makers.

Reasons to Purchase
Review P&R trends in the US, based on Datamonitor analysis and primary research conducted with key stakeholders in the industry
Benchmark company performance against best-practice P&R recommendations to develop stronger P&R strategies
Gain insight into how P&R fits into drug company strategy in the US and identify specific opportunities and threats within this area